Location
Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Overview:
Acute myeloid leukemia is a type of blood cancer,affects white blood cells. It enables progress rapidly, requires immediate treatment. Acute myeloid leukemia symptoms develop over a few weeks and become increasingly more severe. Symptoms may include tiredness, pale skin, breathlessness and unusual & frequent bleeding.
If symptoms are persisted, diagnostic tests may include blood tests, bone marrow test, lumbar puncture and sometimes genomic testing may be suggested. There is no specific cure available for acute myeloid leukemia. But it is treated by the combination of therapies that include chemotherapeutic agents, stem cell transplantation, radiation therapy and targeted therapy.
Segmentation:
Acute myeloid leukemia pipeline drugs are segmented based onroute of administration, trial phase,and company
By Route of Administration, acute myeloid leukemia pipeline drugs are segmented into
By Trial Phase, Acute Myeloid Leukemia pipeline drugs are segmented into
By Company, Acute Myeloid Leukemia pipeline drugs are segmented into
Space Analysis:
Many of the drugs and treatments are being developed under the clinical trials for the treatment of acute myeloid leukemia. Companies are looking for the most effective chemotherapy drugs while still avoiding the side effects. Some of the chemotherapeutics drugs under clinical trials include sapacitabine, tipifarnib,andbortezomib. Furthermore, immunotherapies and stem cell therapies also effectively studying by the researchers to treat the acute myeloid leukemia. In addition, targeted therapy class of drugs such as FLT3 Inhibitors, Histone deacetylase inhibitors,and aurora kinase inhibitors are the promising for the treatment of acute leukemia.
Report Description:
Acute Myeloid Leukemia Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Acute Myeloid Leukemia Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
Location
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary
Â
2. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Introduction
Â
2.1. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Taxonomy
2.2. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market –Definitions
2.2.1. Route of Administration
2.2.2. Trail Phase
Â
3. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
3.6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market – Competition Landscape
3.7. Epidemiology
Â
4. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market opportunity analysis
Â
5. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market, By Route of Administration, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.1. Oral
5.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
Â
5.2. Parenteral
5.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
Â
5.3. Others
5.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
Â
6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market, By Trial Phase, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.1. Pre-clinical phase
6.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
Â
6.2. Phase-I
6.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
Â
6.3. Phase II
6.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
Â
6.4. Phase-III
6.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
Â
7. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
Â
7.2. Europe
7.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
Â
7.3. Asia-Pacific
7.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
Â
7.4. Latin America
7.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
Â
7.5. Middle East and Africa
7.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024
Â
8. North America Acute Myeloid Leukemia Pipeline Drugs Assessment MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
8.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
8.1.1. Oral
8.1.2. Parenteral
8.1.3. Others
Â
8.2. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Pre-clinical phase
8.2.2. Phase-I
8.2.3. Phase II
8.2.4. Phase-III
Â
8.3. Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024
8.5. North America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends
Â
9. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
9.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Oral
9.1.2. Parenteral
9.1.3. Others
Â
9.2. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Pre-clinical phase
9.2.2. Phase-I
9.2.3. Phase II
9.2.4. Phase-III
Â
9.3. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
Â
9.4. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024
9.5. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends
Â
10. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
10.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Oral
10.1.2. Parenteral
10.1.3. Others
Â
10.2. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Pre-clinical phase
10.2.2. Phase-I
10.2.3. Phase II
10.2.4. Phase-III
Â
10.3. Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)Â Â Â Â Â Â Â
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
Â
10.4. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024
10.5. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends
Â
11. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2012 - 2012 - 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
11.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Oral
11.1.2. Parenteral
11.1.3. Others
Â
11.2. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Pre-clinical phase
11.2.2. Phase-I
11.2.3. Phase II
11.2.4. Phase-III
Â
11.3. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
Â
11.4. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024
11.5. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends
Â
12. Middle East and Africa Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
12.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Oral
12.1.2. Parenteral
12.1.3. Others
Â
12.2. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Pre-clinical phase
12.2.2. Phase-I
12.2.3. Phase II
12.2.4. Phase-III
Â
12.3. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
Â
12.4. MEA Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 – 2024
12.5. MEA Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics – Trends
Â
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Cyclacel Pharmaceuticals Inc. (U.S.)
13.2.2. Johnson & Johnson Services, Inc. (U.S.)
13.2.3. Novartis AG (Switzerland)
13.2.4. H. BoehringerSohn AG &Ko. KG (Germany)
Â
14. Research Methodology
15. Key Assumptions and Acronyms